Universal Detection Technology responds to HSPH survey on anthrax threat

NewsGuard 100/100 Score

Universal Detection Technology (www.udetection.com) (OTCBB: UNDT), a developer of early-warning monitoring technologies and counter-terrorism training programs to protect people from bioterrorism and other infectious health threats, responded today to a survey that says nearly a third of Americans would delay in taking an antibiotic recommended by public health officials in the wake of an anthrax detect.

“Once a positive identification of a trace of anthrax is found, prophylactic antibiotics can be administered to first responders and others that might have come into contact with the deadly bioagent”

The poll, conducted by the Harvard School of Public Health (HSPH), found that if Americans were faced with a significant anthrax threat in their city or town, 89 percent would follow public health officials’ recommendations for prophylactic antibiotics; however, over a third of those respondents (39 percent), would delay in taking those medications.

“Once a positive identification of a trace of anthrax is found, prophylactic antibiotics can be administered to first responders and others that might have come into contact with the deadly bioagent,” said Jacques Tizabi, CEO of Universal Detection Technology. “UNDT’s 5 agent biodetection kits can detect the presence of anthrax and four other agents commonly used as bioweapons in as little as three minutes, allowing for the immediate and appropriate health response to prevent deadly illness,” continued Tizabi.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Navigating the complexities of controlled release drug formulations